VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
+18.09%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$225M
AUM Growth
+$225M
(+83%)
Cap. Flow
+$117M
Cap. Flow
% of AUM
51.9%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
2
Increased
–
Reduced
1
Closed
–
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$75.7M |
| 2 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$54.5M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$13.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Akero Therapeutics
AKRO
$3.74B
| $75.7M | 33.61% | +3,954,858 | New | +$75.7M |
|
2
Precision BioSciences
DTIL
$57.8M
| $56.5M | 25.08% | 4,265,141 | – | – |
|
|
TPTX
3
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $54.5M | 24.21% | +1,340,265 | New | +$54.5M |
|
|
4
Apellis Pharmaceuticals
APLS
$3.48B
| $25.3M | 11.24% | 1,000,000 -526,122 | -34% | -$13.3M |
|
5
VYNE Therapeutics
VYNE
$8.16M
| $8.76M | 3.89% | 1,461,552 | – | – |
|
|
VRNA
6
Verona Pharma
VRNA
$9.16B
| $4.46M | 1.98% | 875,000 | – | – |
|